A Chinese drug maker has received approval from the Food and Drug Administration to start clinical trials in the US for a breakthrough Alzheimer’s drug as it seeks global validation for the controversial therapy.
Shanghai Green Valley Pharmaceutical got clearance on April 8 for the US part of a global trial that seeks to enrol more than 2,000 patients with mild-to-moderate Alzheimer’s across North America, Europe and Asia, according to a company statement on Sunday.
The drug maker, which did not disclose the size of US trials and still needs permission from other countries, aims to file for FDA approval to sell the drug by 2025 after the trial concludes. The start of the US trial may be delayed by the coronavirus pandemic but will not impact its long-term timeline, said Li Jinhe, the company’s vice-president of global operations.
FDA’s move to let Green Valley go straight to late-stage large-scale trials is a boost to its bid for global legitimacy after the experimental drug oligomannate received conditional approval in China late last year. It’s the first new medicine for the incurable neurodegenerative disorder in nearly 17 years but there’s been scepticism from researchers over its unusual approach and efficacy.
Global drug makers have invested billions of dollars in over 190 experimental drugs to treat Alzheimer’s, which affects 10 million people in China and 5.8 million in the US, with little to show for it.
Green Valley is "cautiously optimistic" about the clinical tests and the US approval is just the first step in the global multi-Centre phase three trials, Li said in a statement. "It won’t be a success until the drug gets approved."
The trial will be conducted for a year during which neither investigators nor patients will know who’s been given the medicine and who’s on placebo to avoid bias when interpreting results. This will be followed by six months of open study when all the patients will receive the drug.
Researchers estimate there are 50 million people worldwide living with dementia, with Alzheimer’s the cause in as many as 70 per cent of cases. Drugs that halt the debilitating disease could be a market worth as much as US$30 billion in the US alone, according to an estimate by analysts at Sanford C. Bernstein & Co.
The FDA has allowed the Chinese drug maker to skip earlier phases, where the drug is studied on smaller groups of patients, and go straight into the large-scale phase three trials that precedes filing for regulatory approval. The go-ahead highlights the urgent need for an Alzheimer’s treatment, as well as the American regulator’s comfort with data recorded from clinical trials in China.
Oligomannate’s unusual method of slowing down Alzheimer’s has been controversial as it still lacks sufficient evidence in human studies. The drug aims to readjust the microbiome in the gut, which Green Valley says ultimately leads to reduced neuron inflammation in the brain, thus slowing the progression of the disease.
The approach breaks from the pack: in their efforts, global drug makers like Roche Holding and Biogen have focused on a protein called beta amyloid, which forms clumps of plaque in the brain and is thought to be a cause of the disease. But a lack of progress has led to calls from researchers to rethink the industry’s fixation on beta amyloid.
Roche scrapped its drug trials in 2019 after concluding they would fail. Biogen said in October that it planned to file for FDA approval for its experimental Alzheimer’s therapy after relooking data from clinical trials that had earlier seemed disappointing.
It now plans to file for approval in the third quarter, a delay from its earlier goal of an early 2020 submission.
Green Valley, meanwhile, is pressing ahead.
"Good results coming out of the drug trials in China have boosted our confidence," said Li. ‘We believe it will eventually be launched globally to benefit more patients."
CPhI China 2020 To Be Postponed to Dec. 16-18th,
Register as Visitor to the 20th Edition of CPhI China!
-----------------------------------------------------------------------
Editor's Note:
En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,
for any copyright disputes involved in the articles,
please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
